Cargando…

Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254551/ https://www.ncbi.nlm.nih.gov/pubmed/34234470 http://dx.doi.org/10.2147/JAA.S326321

Ejemplares similares

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
por: Menzella, Francesco, et al.
Publicado: (2015)

Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
por: Kay, Dana, et al.
Publicado: (2018)

Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis
por: Alves, José Mario, et al.
Publicado: (2021)

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
por: Pane, Fabrizio, et al.
Publicado: (2022)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2020)

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome
por: Roufosse, Florence, et al.
Publicado: (2023)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
por: Montero-Pérez, Olalla, et al.
Publicado: (2019)

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
por: Qu, Qiuxia, et al.
Publicado: (2020)

Severe Pediatric Asthma Therapy: Mepolizumab
por: Ullmann, Nicola, et al.
Publicado: (2022)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
por: Lachance, Madeleine, et al.
Publicado: (2022)

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome
por: Reiter, Andreas, et al.
Publicado: (2022)

Corrigendum on ‘‘IL-4-C-590T locus polymorphism and susceptibility to asthma in children: a meta-analysis”
por: Jin, Xiaosheng, et al.
Publicado: (2021)

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction [Corrigendum]
Publicado: (2021)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”
por: Hamelmann, Eckard
Publicado: (2019)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]
Publicado: (2023)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
por: Golay, Josée, et al.
Publicado: (2020)

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
por: Roufosse, Florence, et al.
Publicado: (2020)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype
por: González-Pérez, Ruperto, et al.
Publicado: (2022)

Successful use of mepolizumab for severe hypereosinophilic vasculitis with c-ANCA positivity in a previously healthy 7-year-old boy
por: Fox, Eryn, et al.
Publicado: (2022)

Plant Recycling for Molecular Biofarming to Produce Recombinant Anti-Cancer mAb
por: Kim, Deuk-Su, et al.
Publicado: (2016)

Expression and in vitro function of anti-cancer mAbs in transgenic Arabidopsis thaliana
por: Song, Ilchan, et al.
Publicado: (2020)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
por: Wang, Dengli, et al.
Publicado: (2022)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020)

Controlling the Glycosylation Profile in mAbs Using Time-Dependent Media Supplementation
por: Radhakrishnan, Devesh, et al.
Publicado: (2017)

Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Requena, Gema, et al.
Publicado: (2021)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a3pklt4qb7hh5tuo9c75a5iu2u